Login to Your Account



Phase III Stroke Drug Failure Sends Paion Shares Plunging

By Cormac Sheridan


Monday, June 4, 2007
Shares in Paion AG plunged by more than 65 percent Friday on news that the company's clot-busting stroke drug Desmoteplase failed to attain the primary endpoint in a placebo-controlled Phase III clinical trial in acute ischemic stroke. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription